Gyroscope Therapeutics   Report issue

For profit Phase 2
Founded: Stevenage United Kingdom (2017)
Status: Acquired by Novartis (2021)

Organization Overview

First Clinical Trial
2018
NCT03846193
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Gyroscope Therapeutics | Gyroscope Therapeutics Limited

Active Ingredients

Drugs in Phase 2 Trials (1)

gt005 (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anetoderma (Phase 2)

Atrophy (Phase 2)

Eye Diseases (Phase 2)

Geographic Atrophy (Phase 2)

Macular Degeneration (Phase 2)

Retinal Degeneration (Phase 2)

Retinal Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 1